top of page

Who's running the show?

Ryan P. Hamer (BSc, MBA)

Managing Director

  • Grey LinkedIn Icon
f14ce151-cdf4-4e56-983b-829224039a35.JPG

Ryan holds a Bachelor of Science from Swinburne University (Melbourne), a postgraduate degree in Management from Griffith University (Brisbane), and has undertaken specialist training in the U.S and the U.K. Ryan’s clinical and research interests focus on complex cortico-subcortical mapping for neuroplasticity in glioma patients, having previously introduced contemporary brain mapping techniques throughout Australia and Singapore. For Ryan, Neuroclast is a vehicle representative of his life's pursuit in applied clinical neuroscience, one that will foster a PhD and the sharing of knowledge and education in science, electrophysiology, and medical devices. Learn more about Neuroclast's research

Ryan is a clinical neuroscientist, healthcare executive and medical device enthusiast based in Melbourne, Australia. Having been involved in clinical neurophysiology for over a decade, he has individually served as Clinical Director and Business Development Manager for two multinational clinical neuroscience and healthcare companies, and has been an invited speaker at medical conferences and meetings around Australia, Asia and South Africa. Ryan is also a Clinical Lecturer with the Faculty of Health and Medicine at the University of Sydney, and Unit Coordinator for intraoperative neurophysiology units as part of the Master of Medicine program. In addition to these roles, Ryan is also an Honorary Fellow and PhD Candidate (Dept. of Neurosurgery, St Vincent's Hospital) with the University of Melbourne, and elected as President of the Intraoperative Neurophysiology Society of Asia-Pacific (INSA) for 2020-2024.

Selected works:

  • Hamer RP, Poonnoose S. Arcuate fasciculus cortico-cortical evoked potentials and direct cortico-subcortical stimulation during awake craniotomy for debulking of left dominant temporal oligodendroglioma. Neurosurg Focus Video. 2025;12(1):V5.

  • Hamer RP, Praeger AJ. Facilitating complete resection of intrinsic motor cortex glioma with titration of high-frequency cortico-subcortical mapping train count informed by navigated transcranial magnetic stimulation: illustrative case. J Neurosurg Case Lessons. 2024;8(2).

  • Hamer RP, Chen A, Gogos A. Bilateral epidural D-wave monitoring during resection of an eccentric cervical astrocytoma with evidence of asymmetrical corticospinal desynchronization. British Journal of Neurosurgery, 31, 1-7.

  • Hamer R. P. & Yeo T. T. (2022). Current status of neuromodulation-induced cortical prehabilitation and considerations for treatment pathways in lower-grade glioma surgery. Life, 12(4), 466:491.

  • Hamer R. P. et al. (2020). Optimizing the onco-functional balance in supratentorial brain tumour surgery: a single institution's initial experience in cortico-subcortical mapping and monitoring in Singapore. Journal of Clinical Neuroscience, 79, 224-230.

RyanHamer_©ShannynHiggins-16_edited.jpg

I’ve spent a considerable amount of my career observing neurosurgeons treat brain cancer patients. That’s why Neuroclast exists; to provide functional information to surgeons who help ensure that these patients maintain a good quality of life. At the moment we have a niche product portfolio and data infrastructure that will permit clinicians and hospitals to optimise patient outcomes and publish their own results with ease. Nexstim in particular represents a tremendous opportunity for me as a scientist, not only to introduce new neuro-imaging techniques in the ANZ region, but also to contribute to our over-arching pursuit to help preserve life with onco-functional insight, and contribute to the new era of functional localisation of the brain.

Doctors

In the field:

Dr Jessica Sharkey (PhD, BHlthSc Hons)

Clinical Neuroscientist

Sean Carroll (BSc)

Clinical Applications Consultant

Jess completed her undergraduate degree in Health Science (Anatomy & Physiology) with honours in 2016, and was awarded her PhD in June 2021. Jess' research explored the development of animal models for traumatic brain injury. Following her PhD Jess accepted a post-doctoral position involving a novel non-invasive device to monitor brain oxygenation,

JMS_HEADSHOT_2024.png
IMG_376622.heic

Joining the team in July 2024, Sean brings a diverse wealth of project management and leadership experience partnered with his academic foundations in clinical neuroscience. Actively engaged in pre-surgical and intraoperative brain mapping, Sean has also recently assisted in the Australian launch of the SUSy stereotactic system, and shows great interest and

cerebral blood flow and intracranial pressure changes in patients with severe traumatic brain injury, as well as another post-doctoral position with the Perelman School of Medicine at the University of Pennsylvania. Jess joined the team in October 2022.

"I remember my first day like it was yesterday. I was welcomed by a big leather office chair at my very own desk and a large projection plastered on the upstairs wall - “Welcome Dr Sharkey!”. Seven hours of education left Ryan to lose his voice and me realising that I knew nothing. This was a completely fresh start.

Brain mapping is an art. When I started, the prospect of being able to execute intraoperative mapping honestly seemed straightforward, which I find hilarious in retrospect. It involves an understanding of surgical manoeuvres, neuroanatomy, neuroscience and knowing when to push and when to stop. It involves trust from your surgeon and trust within yourself. You must understand specific signatures and not knee jerk react to signal change."

enthusiasm toward clinical electrophysiology, neuro-oncology surgery and academia.

"It has been a privilege to be involved with the work being undertaken by Neuroclast and to adopt the overall mission of the company. The insight I have been afforded from patients ahead of their surgeries has at times stirred a wide range of emotions, but left me admiring the reliance of these people and their families. Being involved in nTMS from the get-go has provided a substantial anchor to maintain a mindfulness regarding the lives of each person who enters the OR, the often sudden and recent events that have brought them to surgical intervention, and why they are choosing to be there."

Doctors

Why are we here?

Our goal is to facilitate access to technologies that might reduce the impact of debilitating neurologic injury. A lot of the time these technologies are related to mapping the human brain, though this also involves technology relating to virtual reality and electrophysiology. 

First and foremost, we invest in our employees. We're committed to building an environment that fosters professional growth in order to meet the needs of clinicians and patients.

We invest in the technology of our business partners, and generate revenue for new business partners, to introduce various medical technologies to ANZ.

We will also distribute a portion of revenue towards novel research and development relating to neuroscience, neurosurgery and electrophysiology. This will also involve co-sponsorship of research funding with academic and medical institutions. 

As a company, we are dedicated to finding ways to assist clinicians in their plight against brain cancer and neurodegenerative disease, and meaningfully contributing to clinical education and research. More often than not, this means partnering with world-class medical device companies around the world to introduce their technology in ANZ.

We look to employ people that are independently minded and lateral thinkers that are solutions-oriented. We are also hell-bent on the fostering and development of graduate professionals entering the healthcare and medtech industry. 

We're also big on transparency. We're a small but growing business, and it's important we include our prospective customers with how we're distributing revenue from your interest in our products and services. 

The company also expects to align with various charities and fundraising efforts for these charities to increase awareness of causes and centres related to neurodegenerative disease.

Iconoclast 
icon·​o·​clast | ʌɪˈkɒnəklast

A person who challenges settled beliefs or institutions. If you describe someone as an iconoclast, you mean that they often question dogmatic beliefs and standards that are generally accepted by society, in order to benefit society. 

Neuro 
neu·​ro | nu̇r-ō

Of or relating to the human nervous system.

standalone_logo.png

Neuroclast
neu·​ro·clast | nu̇r-ō-ˌklast

the pursuit of understanding, generated by a collective of persons who respectfully challenge settled beliefs, dogmas or institutions related to applied clinical neuroscience and applications of medical technology, and in collaboration with clinicians, to optimize clinical outcomes for patients.

What's in a name?

bottom of page